AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02458846 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plusoptix Autorefractor
Description: Autorefractors are electronic devices that measure refractive errors by focusing a light onto the child's eyes and recording how their reflections from the retina return to the camera. The Plusoptix has been shown to have high sensitivity and specificity in previous research. AAPOS (2013) guidelines were used to determine the referral criteria.
Study NCT02908867 — intervention group
Intervention type: OTHER
Intervention: Therapeutic Strategies
Description: Using questionnaires (Erectile Function of International Index and American Impairment Scale) and search in public markets using semi structured form
Study NCT02458846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Eye Exam
Description: Children who did not pass all three screening tests were referred for full cycloplegic optometry exams, with a parent/guardian present. Optometrists assessed visual history, monocular visual acuity (near \& far), strabismus, binocular function, abnormalities of the anterior segment, and cycloplegic refraction. If the optometrist prescribed glasses, frames were chosen at the time of the exam and the glasses were dispensed either at school (with an optician) or at the optometrist's office.
Study NCT04215744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ice water immersion
Description: Ice water immersion of the left hands
Study NCT00180687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulised Bupivacaine intraperitoneally
Description: Nebulised Marcaine (Bupivacaine)
Study NCT00180687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Nebulised Normal Saline
Study NCT00180687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injected Bupivacaine intraperitoneally
Description: Injected Marcaine directly into the peritoneal cavity
Study NCT00180687 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No Intraperitoneal Therapeutics
Description: No Intraperitoneal Therapeutics given
Study NCT03647475 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Device: Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by one-month DAPT
Description: To evaluate the clinical safety of the Resolute Onyx stent with use of one-month DAPT in subjects deemed at high risk for bleeding and/or medically unsuitable for more than one-month DAPT treatment.
Study NCT04106440 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Application Use
Description: Use applications after initial diagnosis to share information with study team.
Study NCT00816335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/CT scan
Description: For all patients undergoing a preoperative PET/CT scan on the day of surgery, at approximately 70 minutes post-injection of 18F-FDG, a diagnostic whole body PET/CT scan will be obtained on a Siemens Biograph 16 PET/CT scanner (Siemens, Knoxville, TN).
Study NCT00816335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG Injection
Description: Patients undergoing a preoperative PET/CT scan the day of surgery, are required to have fasted for at least 4 hours prior to the anticipated preoperative PET/CT scan. Patients participating in this pilot study (whether they have had their preoperative PET/CT scan prior to the day of surgery or whether they are having their preoperative PET/CT scan on the day of surgery) will receive a preoperative IV injection into a peripheral vein of 15 mCi of 18FFDG at time interval of approximately 60 to 180 minutes prior to anticipated time of surgery.
Study NCT00816335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative 18F-FDG PET/CT Scan
Description: Patients undergoing preoperative PET/CT scan day of surgery, at approximately 70 minutes post-injection of 18F-FDG, a diagnostic whole body PET/CT scan will be obtained. PET imaging will immediately be preceded by noncontrast transmission CT (for attenuation correction and anatomic correlation purposes) and will be obtained from the base of the skull to the mid thighs. Bed positions will be scanned for 3 minutes each, moving the patient through the scanner in a craniocaudal direction. Once the preoperative PET/CT scan is acquired, images will be reviewed by the nuclear medicine physician and the surgeon.
Study NCT00816335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG for patients with Bladder Cancer
Description: Elimination of 18F-FDG by the urinary system and accumulation in the bladder impacts the differentiation between residual 18F-FDG in the bladder and activity in tumor and adjacent lymph nodes. For patients with bladder cancer, the urinary catheter routinely placed in the operating room will be inserted in the Ambulatory Surgery Unit (ASU) by the urologist on-service or the urology research nurse. A 3-way Foley catheter will be placed for continuous bladder irrigation with Normal Saline (0.9%) initiated in ASU and will continue for the duration of the imaging procedure at a standard rate of 10cc/minute. The urology research nurse will transport the patient to and from the PET/CT area and monitor the continuous bladder irrigation during the imaging session.
Study NCT00816335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Previously determined operative procedure based on type of solid malignancy. Factors include extent and location of disease, physiologic status of patient intraoperatively, any technical considerations influenced by anatomic constraints, and a risk: benefit analysis of proposed procedure. The decision to proceed with resection on these factors, and will constantly re-evaluate during resection to ensure patient well-being, both short and long term, is foremost consideration. Evaluation of extent of disease during surgical exploration will include inspection and palpation of entire area being evaluated. Tissue that is highly suspicious for involvement with metastatic disease that alters the surgical decision making plan of resection will be biopsied or resected for histologic confirmation if feasible and safe. If patient is found to have resectable disease, deemed safe patient, surgeon will continue and proceed with definitive surgical resection with assistance of handheld gamma probe.
Study NCT00816335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Specimen PET/CT Scan
Description: Resected surgical specimen will be placed on top of paraffin block. Digital photos of the specimen will be obtained for visual correlation of specimen placement on paraffin block. Two bed position 10 minute specimen PET/CT scan will be performed on surgical specimen. If remnant tissue is available, a second image maybe acquired via MRI. Images will be processed and reviewed for quality and presence or absence of hypermetabolic foci and correlated with anatomical information provided by CT and MRI imaging that were originally noted in the preoperative clinical PET/CT scan. During the time when the excised surgical specimens are transported to radiology for specimen PET/CT scanning, additional evaluation of these ex-vivo specimens with other tumor detection devices may be undertaken. Specimen will then be transported back to the operating room in order to be sent to and processed by surgical pathology for standard pathologic evaluation.
Study NCT02759003 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nightime NIV initiation
Description: In-hospital vs home
Study NCT02759003 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nightime NIV initiation
Description: In-hospital vs home
Study NCT00427973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally
Study NCT00427973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Peripheral blood was obtained from all patients enrolled for studies of early changes in circulating proangiogenic and proinflammatory molecules and cells. Blood samples were collected in EDTA-containing tubes before and after cediranib therapy on days 1 and 14 of cycle 1. Circulating VEGF, placental growth factor (PlGF), sVEGFR1, basic fibroblast growth factor (bFGF), interleukin (IL)-6, IL-8, transforming growth factor a ((TNF-a), gamma interferon (IFN-g) were measured using multiplex ELISA plates from Meso-Scale Discovery. Hepatocyte growth factor (HGF), insulin-like growth factor 1 (IGF-1), sVEGFR2, angiopoietin 2 (Ang-2), sTie2, soluble c-KIT, carbon anhydrase 9 (CAIX), and stromal cell-derived factor-1a (SDF1a) were measured using ELISA kits from R\&D Systems.
Study NCT01425788 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Osiris Phleum pratense
Study NCT00427973 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: computed tomography (CT) every 8 weeks to evaluate response and progression.
Study NCT00427973 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: Magnetic resonance imaging (MRI) every 8 weeks to evaluate response and progression.
Study NCT00427973 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Blood samples to characterize the steady-state PK of cediranib were drawn from a peripheral vein shortly before patients received the dose on days 8 and 15 of cycle 1 and at the following times relative to dosing on day 1 of cycle 2: 5 min and 1, 2, 4, 6, 8, and 24 hours, with the last sample collected before taking the next daily dose.
Study NCT02708459 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: surgically inserted Transversus abdominus plane catheter
Description: at end of surgery, a surgeon will insert catheter in Transversus abdominus plane (TAP) between internal oblique muscle and Transversus abdominus muscle
Study NCT02708459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous morphine
Description: Boluses of intravenous morphine (2 mg) will be given to patients if Visual analogue scale (VAS) more than 3
Study NCT03771053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe with simvastatin
Description: ezetimibe 10mg with simvastatin 40mg everyday for 12 months after PCI
Study NCT03771053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: simvastatin 40mg everyday for 12 months after PCI
Study NCT00267189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: 1.5 mg bid adjusted in order to achieve a trough level between 3 and 8 ng/mL while in combination with CNI and between 6 and 12 ng/mL after CNI discontinuation
Study NCT00267189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcineurin inhibitors (CNI)
Study NCT00267189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcineurin inhibitors (CNI)
Study NCT00267189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate acid (MPA)/ Azathioprine (AZA)
Study NCT00267189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Study NCT00267189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Study NCT01160718 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fulvestrant
Description: Arm A: Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days Arm B: Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days
Study NCT01160718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: selumetinib
Description: AZD6244 75 mg p.o. bid
Study NCT00777205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-based peer support
Description: Patients received a) a peer-support manual that outlines self-management and recovery principles and provides peer discussion topics and b) access to a specialized telephone platform that permits free calls to their partners, ready access to mental health staff for back-up and advice on being effective partners, and recorded tips on depression management. They were asked to call their peer partner at least once a week for 24 weeks.
Study NCT00777205 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Patients received their usual mental health care plus a copy of the Depression Helpbook by Wayne Katon and bi-weekly study mailings with depression management tips.
Study NCT00777205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care
Description: Patients received their usual mental health care plus a copy of the Depression Helpbook by Wayne Katon and bi-weekly study mailings with depression management tips.
Study NCT00751621 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IgPro20
Study NCT00655460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: glucose control with computer generated recommendations
Description: Insulin dosing will be recommended by the computer tools based on subject glucose values. Bedside clinicians will have the ablity to accept or reject the suggested dose.
Study NCT02200783 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TripTable
Description: Details of the device previously described, designed to medical operator radioprotection. No changes in radial technique beyond the use of the supportive device will be performed.
Study NCT02200783 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radial
Description: Standard radial artery catheterization procedure, performed for the purpose of coronary angiography and ad hoc angioplasty if necessary.
Study NCT02200783 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral
Description: Standard femoral artery catheterization procedure, performed for the purpose of coronary angiography and ad hoc angioplasty if necessary. The supporting device will be the patient's own body, placing the material above the legs.
Study NCT03617354 — intervention group
Intervention type: PROCEDURE
Intervention: Total Laparoscopic Hysterectomy
Description: The trainee gynaecologists are undertaking a training program in performing Total Laparoscopic Hysterectomy
Study NCT05041517 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BOLT + PTC
Description: BOLT is a Brief Online Training (BOLT) for Measurement-Based Care (MBC). Participants in the BOLT condition were subsequently randomized into varying amounts of post-training consultation (PTC).
Study NCT03555435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moving Forward On Your Own
Description: Participants in this group will use the online program on their own for 6 weeks.
Study NCT03555435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moving Forward with Peer Support
Description: Participants in this group will use the online program on their own for 6 weeks with the support of a peer coach. Peer coaching sessions will consist of 6 15-20 minute sessions one time per week. Sessions will be guided by a Moving Forward Peer Support Manual.
Study NCT02708459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupevecaine
Study NCT02708459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomedine
Study NCT03770377 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Perturbation to Continuous Perturbation
Description: Manipulate the Movement Planning Period (MPP), by interrupting sensory predictions by removing e-stim during the inter-trial interval (Intermittent Perturbation), followed by a washout/de-adaptation period.
Study NCT03770377 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Perturbation to Continuous Perturbation
Description: Manipulate the Movement Planning Period (MPP), by interrupting sensory predictions by removing e-stim during the inter-trial interval (Intermittent Perturbation), followed by a washout/de-adaptation period.
Study NCT03770377 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Perturbation to Intermittent Perturbation
Description: Manipulate the Movement Planning Period (MPP), by keep sensory input about the perturbation constant by maintaining e-stim during the inter-trial interval.
Study NCT03770377 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Perturbation to Intermittent Perturbation
Description: Manipulate the Movement Planning Period (MPP), by keep sensory input about the perturbation constant by maintaining e-stim during the inter-trial interval.
Study NCT04426487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Progesterone
Description: Intramusculer progesterone
Study NCT03555435 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wait
Description: Participants in this group will wait 6 weeks.
Study NCT04354727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-1252
Description: infusion once weekly
Study NCT04426487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Intramusculer progesterone
Study NCT02256969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Blephamide
Study NCT02256969 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GenTeal PM Night-Time
Study NCT02256969 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Meibomian Gland Probing
Description: For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. After obtaining adequate anesthesia, the solid stainless steel probes (Maskin® Meibomian Gland Intraductal Probes, Rhein Medical Inc.) were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were initially be probed with a 1-mm probe followed by a 2-mm probe for all glands.
Study NCT02256969 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Meibomian Gland Probing
Description: For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. After obtaining adequate anesthesia, the solid stainless steel probes (Maskin® Meibomian Gland Intraductal Probes, Rhein Medical Inc.) were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were initially be probed with a 1-mm probe followed by a 2-mm probe for all glands.
Study NCT02256969 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sham Meibomian Gland Probing
Description: For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. The patient's lid margin was touched with the probes without actual probing of the meibomian gland orifices.
Study NCT00513903 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal intervention
Description: Minimal intervention patients will be seen by a clinical pharmacist during the hospitalization period to improve continuity of pharmacy care following hospital discharge.
Study NCT00513903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention
Description: Enhanced intervention patients will be visited in the hospital and will also be called by the clinical pharmacist following discharge to follow-up on any problems that might have developed after discharge.
Study NCT03347045 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Trimodal Prehab & ERP
Description: 1-hr daily exercise will be completed a total of 5d/week, of which 2 of these sessions are completed through a community fitness center. Following these sessions, the participant will consume a high-protein oral supplement.~Additionally, during the program, participants will be given the option of attending a stress-reduction group and will receive a take-home anxiety-reduction program. They will have access to a physiotherapist, kinesiologist, registered dietitian, and physician throughout the program.~The total length of this program is 8-weeks and is timed to occur in the waiting period between the consent for surgery and operation date.
Study NCT03347045 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Prehab; ERP Alone
Description: 1-hr daily exercise with a self-completed home-exercise program. The participant will be given nutritional education material and a take-home anxiety-reduction program. They will be responsible for maintaining a journal of their activity.
Study NCT00953160 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutera Radio Frequency Device
Description: Up to three treatments, one pass, dosage range of 15-60 kJ.
Study NCT04354727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: taken orally twice a day
Study NCT02460588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroid (prednisolone)
Description: All patients will receive non experimental medication with high dose of corticosteroid.
Study NCT00401622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OneTouch® Ultra®2 System
Description: Education and self-monitoring of blood glucose performed with OneTouch® Ultra®2 System that includes the Simple Start™ home-based education program
Study NCT00401622 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard education and self-monitoring of blood glucose performed with traditional meter systems